386 related articles for article (PubMed ID: 34061126)
1. Inclisiran in dyslipidemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
[TBL] [Abstract][Full Text] [Related]
2. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
3. Inclisiran for the treatment of dyslipidemia.
Nishikido T; Ray KK
Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
[TBL] [Abstract][Full Text] [Related]
4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
5. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.
Kosmas CE; Muñoz Estrella A; Sourlas A; Silverio D; Hilario E; Montan PD; Guzman E
Diseases; 2018 Jul; 6(3):. PubMed ID: 30011788
[TBL] [Abstract][Full Text] [Related]
6. Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Sinning D; Landmesser U
Curr Cardiol Rep; 2020 Oct; 22(12):176. PubMed ID: 33089390
[TBL] [Abstract][Full Text] [Related]
7. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.
Warden BA; Duell PB
J Cardiovasc Pharmacol; 2021 Aug; 78(2):e157-e174. PubMed ID: 33990512
[TBL] [Abstract][Full Text] [Related]
8. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran.
Wilkinson MJ; Bajaj A; Brousseau ME; Taub PR
J Am Heart Assoc; 2024 Mar; 13(6):e032031. PubMed ID: 38456415
[TBL] [Abstract][Full Text] [Related]
9. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
10. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
[TBL] [Abstract][Full Text] [Related]
11. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
13. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
[TBL] [Abstract][Full Text] [Related]
14. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
Tziomalos K
Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
[TBL] [Abstract][Full Text] [Related]
15. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 Biology and Its Role in Atherothrombosis.
Barale C; Melchionda E; Morotti A; Russo I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
[TBL] [Abstract][Full Text] [Related]
17. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
18. Inclisiran-Silencing the Cholesterol, Speaking up the Prognosis.
Rogula S; Błażejowska E; Gąsecka A; Szarpak Ł; Jaguszewski MJ; Mazurek T; Filipiak KJ
J Clin Med; 2021 Jun; 10(11):. PubMed ID: 34199468
[TBL] [Abstract][Full Text] [Related]
19. Development of Novel siRNA Therapeutics: A Review with a Focus on Inclisiran for the Treatment of Hypercholesterolemia.
Ebenezer O; Comoglio P; Wong GK; Tuszynski JA
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835426
[TBL] [Abstract][Full Text] [Related]
20. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B
Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
